• Full year sales grew 2% (cc, +1% USD) as strong performance of our growth drivers, including Cosentyx and Entresto, more than offset Gleevec/Glivec generic erosion:
    • Cosentyx grew to USD 2.1 billion in 2017, USD 615 million in Q4
    • Entresto grew to USD 507 million in 2017, USD 185 million in Q4
    • Oncology excluding Gleevec/Glivec grew 10% (cc), with 13% (cc) growth in Q4
  • Full year 2017 core[1] operating income was broadly in line with prior year (0% cc …
  • Collaboration aims to help patients worldwide gain access to a range of high-quality, affordable immunology and oncology biologics
  • Partnership will be an important part of Sandoz and Biocon strategy to address the next wave of biosimilar opportunities globally
  • Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars
  • Partnership provides foundation for expansion of portfolio 

Holzkirchen, 18 January 2018 – Sandoz, a Novartis …

  • Adalimumab is an anti-TNF medicine used to treat a range of immunological diseases[1]
  • The comprehensive data package provided is expected to demonstrate that Sandoz proposed biosimilar adalimumab matches the reference biologic medicine in terms of safety, efficacy and quality[2]-[4]

Holzkirchen, January 16, 2018 – Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k …